---
title: "LIFERIVER released its performance for the first three quarters, with a net loss attributable to the parent company of 29.38 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263260781.md"
description: "According to the Zhitong Finance APP, LIFERIVER disclosed its third-quarter report for 2025, stating that the company's revenue for the first three quarters was 90.43 million yuan, a year-on-year decrease of 34.27%; the net profit attributable to the parent company was a loss of 29.38 million yuan; the net profit excluding non-recurring gains and losses was a loss of 37.25 million yuan; basic earnings per share were -0.16 yuan"
datetime: "2025-10-29T10:21:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263260781.md)
  - [en](https://longbridge.com/en/news/263260781.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263260781.md)
generator: "portal-rs"
---

# LIFERIVER released its performance for the first three quarters, with a net loss attributable to the parent company of 29.38 million yuan

According to the Zhitong Finance APP, LIFERIVER (688317.SH) disclosed its third-quarter report for 2025, stating that the company achieved revenue of 90.43 million yuan in the first three quarters, a year-on-year decrease of 34.27%; the net profit attributable to shareholders was a loss of 29.38 million yuan; the net profit excluding non-recurring gains and losses was a loss of 37.25 million yuan; basic earnings per share were -0.16 yuan

### Related Stocks

- [688317.CN](https://longbridge.com/en/quote/688317.CN.md)

## Related News & Research

- [12:25 ETMarquis Who's Who Honors Kristan Veora Rollins-Miskell](https://longbridge.com/en/news/296381024.md)
- [UNM and ScienceSoft Launch First Statewide WHO Healthy Aging Initiative in US](https://longbridge.com/en/news/296641162.md)
- [Hengrui Pharma Advances 2026 Employee Stock Ownership Plan Using Existing A Shares](https://longbridge.com/en/news/296370263.md)
- [Sunshine Lake Pharma sets board meeting to review interim results, consider dividend](https://longbridge.com/en/news/296324409.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**